U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H29N5O3
Molecular Weight 435.5188
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VALSARTAN

SMILES

CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=NN=NN3)[C@@H](C(C)C)C(O)=O

InChI

InChIKey=ACWBQPMHZXGDFX-QFIPXVFZSA-N
InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1

HIDE SMILES / InChI
Molecular Formula C24H29N5O3
Molecular Weight 435.5188
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:30:46 UTC 2023
Edited
by admin
on Fri Dec 15 16:30:46 UTC 2023
Record UNII
80M03YXJ7I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VALSARTAN
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
VALSARTAN COMPONENT OF COPALIA
Brand Name English
COPALIA COMPONENT VALSARTAN
Brand Name English
VALSARTAN COMPONENT OF VALTURNA
Common Name English
L-VALINE, N-(1-OXOPENTYL)-N-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-
Systematic Name English
VALSARTAN [VANDF]
Common Name English
VALSARTAN COMPONENT OF EXFORGE HCT
Common Name English
BYVALSON COMPONENT OF VALSARTAN
Common Name English
IMPRIDA-HCT COMPONENT VALSARTAN
Brand Name English
NSC-758927
Code English
CGP 48933
Code English
DIOVAN HCT COMPONENT VALSARTAN
Common Name English
VALSARTAN [EMA EPAR]
Common Name English
VALSARTAN [MI]
Common Name English
VALSARTAN [USP MONOGRAPH]
Common Name English
VALTURNA COMPONENT VALSARTAN
Brand Name English
VALSARTAN [USAN]
Common Name English
VALSARTAN [ORANGE BOOK]
Common Name English
VALSARTAN [EP IMPURITY]
Common Name English
VALSARTAN [MART.]
Common Name English
VALSARTAN COMPONENT OF IMMPRIDA
Brand Name English
VALSARTAN COMPONENT OF DIOVAN HCT
Common Name English
Valsartan [WHO-DD]
Common Name English
EXFORGE COMPONENT VALSARTAN
Brand Name English
VALSARTAN COMPONENT OF EXFORGE
Brand Name English
DIOVAN
Brand Name English
DAFIRO COMPONENT VALSARTAN
Brand Name English
VALSARTAN [HSDB]
Common Name English
VALSARTAN COMPONENT OF ENTRESTO
Brand Name English
AGSAV301 COMPONENT VALSARTAN
Common Name English
COPALIA-HCT COMPONENT VALSARTAN
Brand Name English
EXFORGE HCT COMPONENT VALSARTAN
Common Name English
VALSARTAN [USP-RS]
Common Name English
VALSARTAN [JAN]
Common Name English
VALSARTAN COMPONENT OF DAFIRO-HCT
Brand Name English
VALSARTAN COMPONENT OF COPALIA-HCT
Brand Name English
VALSARTAN COMPONENT OF BYVALSON
Common Name English
ENTRESTO COMPONENT VALSARTAN
Brand Name English
VALSARTAN [EP MONOGRAPH]
Common Name English
PREXXARTAN
Brand Name English
IMPRIDA COMPONENT VALSARTAN
Brand Name English
valsartan [INN]
Common Name English
VALSARTAN COMPONENT OF IMPRIDA-HCT
Brand Name English
DAFIRO-HCT COMPONENT VALSARTAN
Brand Name English
N-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-N-VALERYL-L-VALINE
Common Name English
CGP-48933
Code English
Classification Tree Code System Code
WHO-ATC C09CA03
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
EMA ASSESSMENT REPORTS IMPRADA-HCT (WITHDRAWN: HYPERTENSION)
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
WHO-ATC C10BX10
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
EMA ASSESSMENT REPORTS EXFORGE (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
FDA ORPHAN DRUG 494115
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
WHO-VATC QC09CA03
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
NDF-RT N0000175561
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
WHO-ATC C09DX02
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
EMA ASSESSMENT REPORTS COPALIA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
WHO-ATC C09DX01
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
WHO-VATC QC09DA03
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
EMA ASSESSMENT REPORTS EXFORGE-HCT (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
NCI_THESAURUS C66930
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
WHO-ATC C09DB08
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
EMA ASSESSMENT REPORTS DARFIRO-HCT (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
LIVERTOX NBK547944
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
EMA ASSESSMENT REPORTS COPALIA-HCT (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
WHO-ATC C09DA03
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
NDF-RT N0000000070
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
EMA ASSESSMENT REPORTS DAFIRO (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
WHO-VATC QC09DX01
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
EMA ASSESSMENT REPORTS IMPRIDA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
WHO-ATC C09DX05
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
WHO-ATC C09DX04
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
WHO-VATC QC09DX02
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
WHO-ATC C09DB01
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
WHO-VATC QC09DB01
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
Code System Code Type Description
NSC
758927
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
DAILYMED
80M03YXJ7I
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
INN
7016
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
RXCUI
69749
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY RxNorm
CAS
137862-53-4
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
IUPHAR
3937
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
ChEMBL
CHEMBL1069
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
FDA UNII
80M03YXJ7I
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
MESH
C081489
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
WIKIPEDIA
VALSARTAN
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
SMS_ID
100000088000
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
RS_ITEM_NUM
1708762
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
HSDB
7519
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
EPA CompTox
DTXSID6023735
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
DRUG BANK
DB00177
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
NCI_THESAURUS
C47781
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
LACTMED
Valsartan
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
DRUG CENTRAL
2806
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
CHEBI
9927
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
USAN
HH-50
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
MERCK INDEX
m11372
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY Merck Index
PUBCHEM
60846
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
EVMPD
SUB00017MIG
Created by admin on Fri Dec 15 16:30:46 UTC 2023 , Edited by admin on Fri Dec 15 16:30:46 UTC 2023
PRIMARY
Related Record Type Details
PEPT-1
TRANSPORTER -> INHIBITOR
OAT-1
TRANSPORTER -> INHIBITOR
TYPE-1 ANGIOTENSIN II RECEPTOR
TARGET -> INHIBITOR
Structure of SACUBITRIL VALSARTAN SODIUM HYDRATE
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of VALSARTAN
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
OAT-4
TRANSPORTER -> INHIBITOR
Structure of VALSARTAN
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
OAT-3
TRANSPORTER -> INHIBITOR
OATP1B1
TRANSPORTER -> INHIBITOR
Structure of VALSARTAN MONOSODIUM
SALT/SOLVATE -> PARENT
PEPT-2
TRANSPORTER -> INHIBITOR
Structure of VALSARTAN DISODIUM
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of VALERYL-4-HYDROXYVALSARTAN
METABOLITE INACTIVE -> PARENT
Structure of VALERYL-4-HYDROXYVALSARTAN
METABOLITE INACTIVE -> PARENT
Valsartan was metabolized to a small extent only. The only notable metabolite in plasma, urine and faecs
MAJOR
FECAL; PLASMA; URINE
Related Record Type Details
Structure of VALSARTAN BENZYL ESTER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-NITROSODIETHYLAMINE
IMPURITY -> PARENT
Probable human carcinogen.
Structure of METHYL N-((2'-CYANO(1,1'-BIPHENYL)-4-YL)METHYL)-L-VALINATE
IMPURITY -> PARENT
Structure of VALSARTAN BENZYL ESTER
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of VALSARTAN, D-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-(N-((2'-CYANO-(1,1'-BIPHENYL)-4-YL)METHYL)PENTANAMIDO)-3-METHYLBUTANOIC ACID, (2S)-
IMPURITY -> PARENT
Structure of BENZYL(METHYL)NITROSAMINE
IMPURITY -> PARENT
Priority toxic pollutant.
Structure of DESPENTANOYL BUTANOYL VALSARTAN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DESPENTANOYL BUTANOYL VALSARTAN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-(1-OXOPENTYL)-N-((2'-(2H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-L-VALINE METHYL ESTER
IMPURITY -> PARENT
Structure of VALSARTAN, D-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-((2'-CYANO(1,1'-BIPHENYL)-4-YL)METHYL)-N-(1-OXOPENTYL)-L-VALINE METHYL ESTER
IMPURITY -> PARENT
Structure of N-NITROSODIMETHYLAMINE
IMPURITY -> PARENT
NDMA is an organic chemical that is in a family of potent carcinogens.
Related Record Type Details
Structure of VALSARTAN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

MAXIMUM TOLERATED DOSE TOXICITY
PROTEIN BINDING PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

RENAL CLEARANCE PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966